Healthy Volunteers
Item
1. status : parts a and c: healthy subjects
boolean
C1708335 (UMLS CUI [1])
Patients Non-Insulin-Dependent Diabetes Mellitus
Item
parts b and d: type 2 diabetes mellitus patients :
boolean
C0030705 (UMLS CUI [1,1])
C0011860 (UMLS CUI [1,2])
Body mass index
Item
2. body mass index : parts a and c: 18.0 - 30.0 kg/m2
boolean
C1305855 (UMLS CUI [1])
Body mass index
Item
parts b and d: 25.0 - 35.0 kg/m2
boolean
C1305855 (UMLS CUI [1])
Hemoglobin A1c measurement | Antidiabetics Oral Quantity
Item
3. hba1c : parts b and d: at screening between 6.5% and 9.0%, inclusive for patients using one oral anti-diabetic medication, and between 6.0% and 8.5%, inclusive for patients using two or more oral anti-diabetic medications
boolean
C0474680 (UMLS CUI [1])
C0935929 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
Fasting blood glucose measurement
Item
4. fasting blood glucose : parts b and d: within 7.5-13.5 mmol/l, inclusive at entry into the clinical research center (day -1 for part b or day -2 for part d)
boolean
C0428568 (UMLS CUI [1])
Childbearing Potential Contraceptive methods | Hormonal contraception | Intrauterine Devices | Vaginal contraceptive diaphragm | Gender Contraceptive methods
Item
5. women of childbearing potential agree to use an appropriate contraceptive method (hormonal, iud, or diaphragm) until 90 days after the follow-up visit. for males: willingness to use adequate contraception from entry in the clinical research center until 90 days after the follow-up visit
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C2985296 (UMLS CUI [2])
C0021900 (UMLS CUI [3])
C0042241 (UMLS CUI [4])
C0079399 (UMLS CUI [5,1])
C0700589 (UMLS CUI [5,2])
Abnormality Absent
Item
6. medical history without clinically significant abnormalities
boolean
C1704258 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Antidiabetics Oral Quantity | Metformin | Sulfonylurea | Hypoglycemic Agents Oral | Exception Thiazolidinediones | Absence Pharmaceutical Preparations Changing GLUCOSE CONTROL | Pharmaceutical Preparations chronic Absent | Dietary Supplements Absent
Item
7. parts b and d: taking a stable dose of one or more oral anti-diabetic medications, such as metformin, sulphonylurea or any other orally administered glucose lowering medication (except for thiazolidinediones) for at least 3 months prior to screening. receiving no other chronic medications, including dietary supplements, that alter blood glucose control.
boolean
C0935929 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0025598 (UMLS CUI [2])
C0038766 (UMLS CUI [3])
C0020616 (UMLS CUI [4,1])
C1527415 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C1257987 (UMLS CUI [5,2])
C0332197 (UMLS CUI [6,1])
C0013227 (UMLS CUI [6,2])
C0392747 (UMLS CUI [6,3])
C0726398 (UMLS CUI [6,4])
C0013227 (UMLS CUI [7,1])
C0205191 (UMLS CUI [7,2])
C0332197 (UMLS CUI [7,3])
C0242295 (UMLS CUI [8,1])
C0332197 (UMLS CUI [8,2])
Lying systolic blood pressure Resting | Lying diastolic blood pressure Resting
Item
8. parts a and c: resting supine blood pressure of 140/90 mmhg or lower and higher than 90/50mmhg at screening, and showing no clinically relevant deviations as judged by the principal investigator
boolean
C1319895 (UMLS CUI [1,1])
C0035253 (UMLS CUI [1,2])
C1319896 (UMLS CUI [2,1])
C0035253 (UMLS CUI [2,2])
Lying systolic blood pressure Resting | Lying diastolic blood pressure Resting
Item
9. parts b and d: resting supine blood pressure of 160/100 mmhg or lower and higher than 90/50mmhg at screening, and showing no clinically relevant deviations as judged by the principal investigator
boolean
C1319895 (UMLS CUI [1,1])
C0035253 (UMLS CUI [1,2])
C1319896 (UMLS CUI [2,1])
C0035253 (UMLS CUI [2,2])
Pathology Relevance Clinical
Item
1. evidence of clinically relevant pathology
boolean
C0677042 (UMLS CUI [1,1])
C2347946 (UMLS CUI [1,2])
C0205210 (UMLS CUI [1,3])
Pregnancy | Breast Feeding
Item
2. pregnancy or lactation
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Healthy Volunteers | Pharmaceutical Preparations concomitant | Exception Acetaminophen | Multivitamin preparation allowed | Ascorbic Acid allowed | Status pre- Enrollment | Pharmaceutical Preparations Other To be stopped | Non-Prescription Drugs To be stopped | Supplements To be stopped | Medicinal Herbs To be stopped | ST. JOHN'S WORT EXTRACT To be stopped
Item
3. for healthy volunteers: use of concomitant medication, except for acetaminophen (paracetamol), which is allowed up to 3 days before entry into the clinical research center (after that time the use of a limited amount of acetaminophen is permitted after consultation with the principal investigator). multivitamins and vitamin c are allowed up to 7 days before entry into the clinical research center. all other medication (including over the counter medication, health supplements, and herbal remedies such as st. john's wort extract) must have been stopped at least 14 days prior to entry into the clinical research center.
boolean
C1708335 (UMLS CUI [1])
C0013227 (UMLS CUI [2,1])
C0521115 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0000970 (UMLS CUI [3,2])
C0301532 (UMLS CUI [4,1])
C0683607 (UMLS CUI [4,2])
C0003968 (UMLS CUI [5,1])
C0683607 (UMLS CUI [5,2])
C0332152 (UMLS CUI [6,1])
C1516879 (UMLS CUI [6,2])
C0013227 (UMLS CUI [7,1])
C0205394 (UMLS CUI [7,2])
C1272691 (UMLS CUI [7,3])
C0013231 (UMLS CUI [8,1])
C1272691 (UMLS CUI [8,2])
C0242295 (UMLS CUI [9,1])
C1272691 (UMLS CUI [9,2])
C0025125 (UMLS CUI [10,1])
C1272691 (UMLS CUI [10,2])
C0813171 (UMLS CUI [11,1])
C1272691 (UMLS CUI [11,2])
Study Subject Participation Status | Investigational New Drugs | Clinical Trials Quantity | Gender
Item
4. participation in a drug study within 60 days prior to drug administration. participation in more than 3 other drug studies (for men) / more than 2 other drug studies (for women) in the 10 months preceding the start of this study)
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C0008976 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0079399 (UMLS CUI [4])
Drug screen positive | Opiates | Methadone | Cocaine | Amphetamines | Cannabinoids | Barbiturates | Benzodiazepines | Tricyclic Antidepressive Agents | Alcohol
Item
5. positive drug screen (opiates, methadone, cocaine, amphetamines, cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants and alcohol)
boolean
C0743295 (UMLS CUI [1])
C0376196 (UMLS CUI [2])
C0025605 (UMLS CUI [3])
C0009170 (UMLS CUI [4])
C0002667 (UMLS CUI [5])
C0006864 (UMLS CUI [6])
C0004745 (UMLS CUI [7])
C0005064 (UMLS CUI [8])
C0003290 (UMLS CUI [9])
C0001962 (UMLS CUI [10])
Alcohol consumption U/week | Beer U/week | Wine U/week | Spirits U/week
Item
6. intake of more than 24 units of alcohol per week (one unit of alcohol equals approximately 250 ml of beer, 100 ml of wine or 35 ml of spirits)
boolean
C0001948 (UMLS CUI [1,1])
C0560588 (UMLS CUI [1,2])
C0004922 (UMLS CUI [2,1])
C0560588 (UMLS CUI [2,2])
C0043188 (UMLS CUI [3,1])
C0560588 (UMLS CUI [3,2])
C0301611 (UMLS CUI [4,1])
C0560588 (UMLS CUI [4,2])
Hepatitis B surface antigen positive | Hepatitis C antibody positive | HIV-1 antibody Positive | HIV-2 antibody Positive
Item
7. positive screen on hbsag, anti-hcv or anti-hiv 1/2
boolean
C0149709 (UMLS CUI [1])
C0281863 (UMLS CUI [2])
C0369497 (UMLS CUI [3,1])
C1514241 (UMLS CUI [3,2])
C0369500 (UMLS CUI [4,1])
C1514241 (UMLS CUI [4,2])
Illness Recent
Item
8. illness within 7 days prior to (the first) drug administration
boolean
C0221423 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
Serum creatinine raised
Item
9. serum creatinine > upper limit of the normal (uln) range
boolean
C0700225 (UMLS CUI [1])
Exclusion Criteria Additional | Patients Non-Insulin-Dependent Diabetes Mellitus
Item
additional exclusion criteria specific to type 2 diabetes mellitus patients (part b and part d)
boolean
C0680251 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C0030705 (UMLS CUI [2,1])
C0011860 (UMLS CUI [2,2])
Insulin use Non-Insulin-Dependent Diabetes Mellitus | Thiazolidinediones Non-Insulin-Dependent Diabetes Mellitus
Item
10. the use of insulin and thiazolidinediones for type 2 diabetes mellitus 3 months prior to screening is not allowed.
boolean
C0240016 (UMLS CUI [1,1])
C0011860 (UMLS CUI [1,2])
C1257987 (UMLS CUI [2,1])
C0011860 (UMLS CUI [2,2])
Angiotensin-Converting Enzyme Inhibitors
Item
11. the use of angiotensin converting enzyme (ace) inhibitors 1 month prior to screening is not allowed.
boolean
C0003015 (UMLS CUI [1])
Diabetic Ketoacidosis | Hyperosmolar Hyperglycemic State
Item
12. history of diabetic ketoacidosis or hyperosmolar coma
boolean
C0011880 (UMLS CUI [1])
C3888846 (UMLS CUI [2])
Complications of Diabetes Mellitus Advanced | Neuropathy | Kidney Diseases | Retinal Diseases | Symptoms
Item
13. advanced diabetic complications, including neuropathy, nephropathy, retinopathy or other symptoms
boolean
C0342257 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C0442874 (UMLS CUI [2])
C0022658 (UMLS CUI [3])
C0035309 (UMLS CUI [4])
C1457887 (UMLS CUI [5])